share_log

Seelos Therapeutics | 10-Q: Q2 2024 Earnings Report

Seelos Therapeutics | 10-Q: Q2 2024 Earnings Report

Seelos Therapeutics | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 15:14

Moomoo AI 已提取核心信息

Seelos Therapeutics reported Q2 2024 financial results with net income of $1.7 million compared to a net loss of $29.5 million in Q2 2023. Total revenue was $0.4 million, while operating expenses decreased significantly to $3.5 million from $11.3 million year-over-year. The company ended the quarter with $0.3 million in cash and an accumulated deficit of $253.6 million.The company announced a strategic focus on mental health initiatives and ketamine expertise with SLS-002 in suicidality. In March 2024, Seelos reported topline data from the Phase 2/3 HEALEY ALS Platform trial of SLS-005, showing a 22% improvement in ALSFRS-R assessment in a pre-specified subgroup. Additionally, the company implemented a workforce reduction affecting 33% of employees to reduce operating expenses.Seelos faces near-term challenges including Nasdaq listing compliance requirements and debt covenants. The company must regain compliance with Nasdaq's minimum bid price requirement of $1.00 by October 28, 2024, and the minimum market value requirement of $35 million by August 30, 2024. The company is actively exploring financing options and strategic partnerships to strengthen its financial position.
Seelos Therapeutics reported Q2 2024 financial results with net income of $1.7 million compared to a net loss of $29.5 million in Q2 2023. Total revenue was $0.4 million, while operating expenses decreased significantly to $3.5 million from $11.3 million year-over-year. The company ended the quarter with $0.3 million in cash and an accumulated deficit of $253.6 million.The company announced a strategic focus on mental health initiatives and ketamine expertise with SLS-002 in suicidality. In March 2024, Seelos reported topline data from the Phase 2/3 HEALEY ALS Platform trial of SLS-005, showing a 22% improvement in ALSFRS-R assessment in a pre-specified subgroup. Additionally, the company implemented a workforce reduction affecting 33% of employees to reduce operating expenses.Seelos faces near-term challenges including Nasdaq listing compliance requirements and debt covenants. The company must regain compliance with Nasdaq's minimum bid price requirement of $1.00 by October 28, 2024, and the minimum market value requirement of $35 million by August 30, 2024. The company is actively exploring financing options and strategic partnerships to strengthen its financial position.
Seelos Therapeutics报告了2024年第二季度的财务结果，净利润为170万美元，而2023年第二季度则净亏损2950万美元。总营业收入为40万美元，营业费用显著下降至350万美元，较去年同期的1130万美元大幅减少。公司在本季度结束时现金余额为30万美元，累计赤字为25360万美元。公司宣布战略聚焦于心理健康项目和针对自杀倾向的氯胺酮专业知识，使用SLS-002。在2024年3月，Seelos报告了SLS-005的2/3期HEALEY ALS平台试验的顶线数据，显示在预先指定的亚组中ALSFRS-R评估提高了22%。此外，公司实施了裁员，影响到33%的员工，以减少营业费用。Se...展开全部
Seelos Therapeutics报告了2024年第二季度的财务结果，净利润为170万美元，而2023年第二季度则净亏损2950万美元。总营业收入为40万美元，营业费用显著下降至350万美元，较去年同期的1130万美元大幅减少。公司在本季度结束时现金余额为30万美元，累计赤字为25360万美元。公司宣布战略聚焦于心理健康项目和针对自杀倾向的氯胺酮专业知识，使用SLS-002。在2024年3月，Seelos报告了SLS-005的2/3期HEALEY ALS平台试验的顶线数据，显示在预先指定的亚组中ALSFRS-R评估提高了22%。此外，公司实施了裁员，影响到33%的员工，以减少营业费用。Seelos面临近期挑战，包括纳斯达克上市合规要求和债务契约。公司必须在2024年10月28日之前恢复与纳斯达克最低买盘价格要求1.00美元的合规，并在2024年8月30日之前恢复3500万美元的最低市场价值要求。公司正在积极探索融资期权和战略合作伙伴关系，以加强其财务状况。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    英伟达
    NVDA
    -- 114.060
    特斯拉
    TSLA
    -- 284.650
    Palantir
    PLTR
    -- 83.420
    台积电
    TSM
    -- 172.970
    Strategy
    MSTR
    -- 250.920
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！